BioStock Studio: SynAct Pharma comments on the promising study results in RA

SynAct Pharma has announced top-line results from BEGIN, a phase IIa study of AP1189 in rheumatoid arthritis. The company’s CEO Jeppe Øvlesen and CMO Anders Dyhr Toft came to BioStock’s studio to talk about the study results and the plans going forward.  

See the full interview with SynAct Pharma’s CEO Jeppe Øvlesen och CMO Anders Dyhr Toft below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev